Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece

Current Medical Research and Opinion

Volumn 22, Issue 8, 2006, Pages 1599-1607

  Maniadakis, Nikos ^a   Tzanakis, Nikolaos ^a   Fragoulakis, Vassilis ^b   Hatzikou, Magdalini ^c   Siafakas, Nikolaos ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Found of Economic and Indust Res   (Greece)

^c Boehringer Ingelheim ^*  (Greece)

Author keywords

Chronic obstructive pulmonary disease (COPD); Economic evaluation; Greece; Salmeterol; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; ECONOMIC EVALUATION; GREECE; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; NATIONAL HEALTH SERVICE; QUALITY OF LIFE;

ALBUTEROL; BRONCHODILATOR AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GREECE; HUMANS; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SENSITIVITY AND SPECIFICITY;

EID: 33748086438     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X112778     Document Type: Conference Paper

References (19)

1. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504
2. Sullivan S, Ramsey S. The economic burden of COPD. Chest 2000;117:5S-9
3. Rennard S. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998;113 (Suppl):235S-41
4. Feenstra TL, Van Genugten M, Hoogenveen R, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Resp Crit Care Med 2001;164:590-6
5. Rutten-van Molken M, Postma M, Joore M, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779-87
6. Tzanakis N, Anagnostopoulou U, Filaditaki V, et al. Prevalence of COPD in Greece. Chest 2004;125:892-900
7. Oostenbrink JB, Rutten-van Molken M. Resource use and risk factors in high-source exacerbations of COPD. Respir Med 2004;98:883-91
8. Andersson F, Borg S, Jansson S, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8
9. Oostenbrink JB, Rutten-van Molken M, Monz B, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46
10. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
11. Donohue J, van Noord J, Bateman E, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or Salmeterol. Chest 2002;122:47-55
12. Casaburi R, Mahler D, Jones P, et al. A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
13. Miravitilles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55
14. Donaldson G, Seemungal T, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:846-52
15. Friedman M, Menjoge S, Anton S, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with Chronic Obstructive Pulmonary Disorder (COPD). Pharmacoeconomics 2004;22:741-9
16. Hilleman D, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of chronic obstructive pulmonary disease. Chest 2000;118:1278-85
17. Oostenbrink J, Rutten-van Molken M, Al M, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004;23:241-9
18. Van Hout B, Al MJ, Gordon G, et al. Costs, effects and C/E ratios alongside a clinical trial. Healt Econ 1994;3:309-19
19. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2